Univ. of Maryland researchers develop 'naked eye' COVID-19 test

Novel Coronavirus SARS-CoV-2
The company VitruVian Bio was formed to develop the test for widespread use, and plans to hold pre-submission meetings with the FDA in the coming weeks in pursuit of an emergency authorization. (NIAID - Rocky Mountain Laboratories)

Researchers at the University of Maryland are developing a simple, experimental diagnostic test for COVID-19 that could provide a visual result in 10 minutes, without any laboratory equipment.

Using gold nanoparticles suspended in liquid, the test is designed to react in the presence of the novel coronavirus’s specific genetic material and help diagnose an active infection.

After extracting RNA from a nasal swab or saliva sample, the nanoparticles begin to bind to the virus’s specific proteins—and as the gold begins to cluster, it changes the color of the liquid from purple to blue, a process visible to the naked eye.

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

“Based on our preliminary results, we believe this promising new test may detect RNA material from the virus as early as the first day of infection,” said Dipanjan Pan, professor of diagnostic radiology and nuclear medicine and pediatrics at the university’s school of medicine. 

RELATED: Using water and gold, Australian researchers discover 'universal cancer biomarker'

"The accuracy of any COVID-19 test is based on being able to reliably detect any virus. This means it does not give a false negative result if the virus actually is present, nor a false-positive result if the virus is not present," said Pan. "Many of the diagnostic tests currently on the market cannot detect the virus until several days after infection. For this reason, they have a significant rate of false-negative results."

Pan helped create the company VitruVian Bio to develop the test for widespread use and plans to hold pre-submission meetings with the FDA in the coming weeks in pursuit of an emergency authorization. However, additional studies are still needed to validate the assay, he said. 

The test could be far less expensive to produce than standard COVID-19 molecular tests, and its ease of use could make it well-suited for daycare centers, nursing homes, college campuses or the workplace, according to the researchers, who published their work in the American Chemical Society's nanotechnology journal, ACS Nano.

Suggested Articles

The FDA cleared a miniaturized and disposable sensor patch designed to detect early complications from IV drug infusions.

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Philips announced plans to integrate BioIntelliSense’s health-tracking sticker into its remote patient monitoring programs.